Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| It is early, but we are laying a strong foundation for growth in one of the largest and most unchanged corners of health care |
| Third, with recurring revenue exceeding 50% of total revenue in 2023, we have proven the strength of our business model and demonstrated how we can deliver value well into the future |
| Gross margin expanded for the 11th consecutive quarter with our mix of higher-margin recurring consumable revenue and service and other revenue, representing 66% of total revenue as compared to roughly 59% in Q3 of this year |
| Our fourth quarter gross margin was 26.7%, a more than 100 basis point sequential improvement from the third quarter and a 9.6 percentage point increase from 17.1% in the fourth quarter of 2022 |
| Cartridge utilization continued to perform well, highlighting the strength of our recurring revenue model |
| The unprecedented retention rate in the home and the strong gross margin gains that we've already made with a very, very clear road map now both to this next milestone to 50% gross margins and a very clear road map to a profitable business in addition to a high growth one |
| This distribution highlights the progress we are making within this large market segment and the opportunity for continued long-term growth |
| I think to answer your question, certainly, the return of TabloCart post FDA clearance is expected to be a positive catalyst, point one |
| Additionally, we educated over 400 doctors last year alone, and we've amassed an extensive evidence base, demonstrating the power of Tablo clinically, operationally and economically |
| And that helps tremendously |
| And I think our team is -- that our technology has done a really good job of doing that |
| And maybe lastly, I think a fourth key takeaway is with recurring revenue now over 50% of our total revenue, it gives us a very strong basis off of which to grow with a lot of visibility |
| And so I want to call attention to that and complement our teams across the organization for making that happen, but we do have very high confidence in our ability to meet and exceed expectations on the gross margin front |
| We're very proud of the roughly 10% or 11% penetration we have on the acute side, but that leaves 90% to go |
| With the essential investments behind us in creating a world-class field service, customer success and clinical support organization, we are well positioned to deliver not just an exceptional product but an exceptional, highly differentiated change management experience |
| This is a very difficult to replicate ecosystem, and we enter 2024 in a strong competitive position from which to continue our growth |
| Finally, we expect to deliver operating leverage and to consume substantially less cash in 2024 than we did in 2023 as a result of revenue growth, gross margin expansion and reduced OpEx |
| This is pretty phenomenal when you consider how rapidly our installed base and treatment volume has grown, and we did it while maintaining a 97% uptime across the Tablo installed base and reducing our cost to serve by nearly 25% |
| We continue to make progress building the strong foundation we are establishing for long-term growth |
| We've obviously had strong gross margin gains in 2023 |
| Third, I would say, continued gross margin expansion |
| With the MDOs, which manage dialysis care for about 180,000 patients, which translates to our roughly $9 billion addressable market, we continued to see nice growth in the number and depth of programs offering Tablo |
| Furthermore, we continue to see unparalleled retention rates |
| Our longest tenured patients had dialyzed at home now for 3.5 years, demonstrating Tablo's differentiated patient experience |
| High retention rates not only benefit patients but also help minimize expensive churn for providers |
| We've become exceptional in our field service organization, our clinical support organization and our ability to educate and train physicians and nurses |
| We are pleased to announce that during the fourth quarter, we successfully secured several new sales agreements with skilled nursing facilities, including with one of the nation's largest SNF providers |
| Again, gross margin expansion is driven by console cost-down programs, recurring revenue from our larger installed base and service leverage |
| We remain bullish on the tailwinds in our business and affirm the longer-term guidance we provided in November |
| These partnerships underscore the growing recognition of Tablo's value proposition within the post-acute sector |
| Statement |
|---|
| Product revenue was $22.9 million and a decrease of 13% compared to the $26.4 million in the fourth quarter of 2022 |
| Revenue for the fourth quarter was $30.5 million, in line with our pre-announcement, slightly above the third quarter of 2023 and a decrease of 4.7% compared to $32 million in the fourth quarter of 2022 |
| I also see a market with incumbent competitors that are providing sort of services and products that health systems and patients are increasingly frustrated by and which are driving them to actively seek new solutions |
| We've also seen in the past, overperformance come from ASP and also from more treatment sales than we have modeled |
| Why? Because a hospital or a health system would not perpetuate its use of Tablo within other new hospitals inside of its network if the technology and the experience around it were not delivering on its promises to lower costs and deliver operational and clinical benefits |
| Operating expenses of $36.4 million declined 14% sequentially from the third quarter and 4% from the prior year period, driven in part by the expense reductions we outlined last quarter |
| From Q4 of last year, the largest decrease in spending came from G&A, which declined 15% |
| The change from last year was driven by a decrease in console revenue for the reasons we outlined in the third quarter and was partially offset by an increase in consumables revenue |
| I was just wondering if you can talk a little bit about what the Street is missing about the Outset Medical story |
| We reported a fourth quarter non-GAAP net loss of $29.5 million or $0.59 per share compared to a non-GAAP net loss of $34.1 million or $0.71 per share for the same period in 2022 |
| Net loss was $134.2 million or $2.70 per share compared to a non-GAAP net loss of $135.8 million or $2.82 per share for 2022 |
| We were caught a little flat-footed as we've noted in Q3, Q4, but not so anymore |
Please consider a small donation if you think this website provides you with relevant information